Overview

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Status:
Active, not recruiting
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort to confirm the tolerability.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Adavosertib
MK-1775